$658.79 Million in Sales Expected for Endo International plc (NASDAQ:ENDP) This Quarter

Equities research analysts expect that Endo International plc (NASDAQ:ENDP) (TSE:ENL) will post $658.79 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Endo International’s earnings, with the lowest sales estimate coming in at $651.36 million and the highest estimate coming in at $668.22 million. Endo International reported sales of $634.86 million in the same quarter last year, which indicates a positive year-over-year growth rate of 3.8%. The business is scheduled to announce its next earnings report on Thursday, November 4th.

On average, analysts expect that Endo International will report full-year sales of $2.76 billion for the current financial year, with estimates ranging from $2.74 billion to $2.78 billion. For the next financial year, analysts anticipate that the company will post sales of $2.70 billion, with estimates ranging from $2.55 billion to $2.82 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, August 5th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. Endo International had a negative return on equity of 94.51% and a net margin of 2.46%. The firm had revenue of $713.83 million for the quarter, compared to analysts’ expectations of $657.27 million. During the same period in the prior year, the firm posted $0.65 earnings per share.

ENDP has been the topic of several recent analyst reports. Piper Sandler cut Endo International from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $10.00 to $3.00 in a research report on Tuesday, August 31st. Royal Bank of Canada dropped their price objective on Endo International from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research report on Monday, August 9th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $7.36.

A number of hedge funds have recently bought and sold shares of ENDP. Geode Capital Management LLC lifted its holdings in Endo International by 15.5% in the first quarter. Geode Capital Management LLC now owns 4,105,987 shares of the company’s stock valued at $30,425,000 after acquiring an additional 549,953 shares during the period. Hennion & Walsh Asset Management Inc. bought a new position in Endo International in the first quarter valued at about $3,546,000. LSV Asset Management lifted its holdings in Endo International by 1,928.1% in the second quarter. LSV Asset Management now owns 452,259 shares of the company’s stock valued at $2,116,000 after acquiring an additional 429,959 shares during the period. Alpha Paradigm Partners LLC bought a new position in Endo International in the second quarter valued at about $1,120,000. Finally, Tudor Investment Corp Et Al lifted its holdings in Endo International by 179.8% in the second quarter. Tudor Investment Corp Et Al now owns 355,531 shares of the company’s stock valued at $1,664,000 after acquiring an additional 228,477 shares during the period. 79.73% of the stock is currently owned by institutional investors.

Shares of Endo International stock traded up $0.11 during trading on Friday, hitting $2.83. 8,635,220 shares of the company’s stock traded hands, compared to its average volume of 6,340,223. Endo International has a 1 year low of $1.94 and a 1 year high of $10.89. The stock has a market capitalization of $660.81 million, a P/E ratio of 10.11 and a beta of 1.37. The business has a 50-day simple moving average of $3.50 and a 200-day simple moving average of $5.19.

About Endo International

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals.

Featured Article: Return on Equity (ROE)

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.